Pre-launch orders secured via pharmacies and distributors
VANCOUVER, BC / ACCESSWIRE / July 12, 2022 / EMPOWER CLINICS INC (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) ("Empower" or the "Company") an integrated healthcare company - serving patients through medical centers, telemedicine platforms, a medical device company, and a high complexity medical diagnostics laboratory - announced the launch of its latest product innovation as a leader in at-home testing solutions: new MediSure™ Empower Blood Glucose Monitor (BGM).
A BGM is a small medical device that measures how much glucose (a type of sugar) is in the blood - also known as the blood glucose level. People with diabetes rely on blood glucose monitoring to help them manage their condition. According to government data, more than 40 million people in Canada and US suffer from diabetes.
Fully approved by Health Canada, the new MediSure™ Empower BGM showcases significant improvements including:
"The launch of this cutting edge medical test device for the millions who suffer from diabetes is another example of Medisure's vision to be a global leader for at-home testing solutions," stated Steven McAuley, Chairman and CEO of Empower Clinics. "We know that pharmacies across Canada have been eagerly awaiting the launch of this product because we've already received pre-launch orders. I'm very proud of the entire team at Medisure as they continue to innovative and launch new products - like Vitamin D test kits and this new BGM - that have immediate market adoption with pre-launch orders."
"This new BGM was designed by leveraging all of the strengths of its earlier version that was used for years by thousands of Canadians with diabetes, and by listening to those same loyal clients on how we can improve our solutions," stated Mario Cortis, President of MediSure. "We're excited to launch and share this new BGM because it is a product that was built in partnership with patients, pharmacies and distributors. Pre-launch orders is a testament to their belief in their partnership with Medisure. Based on this partnership model and ethos, we look forward to launching many more at-home testing solutions with our partners."
Through existing distribution partnerships, the MediSure® Empower Blood Glucose Monitoring devices are expected to be available to more than 11,000 pharmacies across Canada next month. Medisure is currently finalizing insurance coverage with public and private health insurers.
The product will also be available for sale at www.medisure.ca and throughout The Medi-Collective clinics.
Additionally, the Company announced that its Board of Directors has approved the grant of incentive stock options for certain Directors, Officers, Employees or Consultants of the Company, pursuant to the Company's Stock Option Plan for the purchase of 1,100,000 common shares at an exercise price of $0.08 per share subject to the vesting provisions of the options, at any time up to and including July 5, 2027.
This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics
Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, a medical device company and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.
ON BEHALF OF THE BOARD OF DIRECTORS:
Chief Executive Officer
Steven McAuley CEO
Business Development & Communications
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include statements regarding:that the MediSure® Empower Blood Glucose Monitoring devices will be available in 11,000 Canadian pharmacies; that the company will be able to finalize insurance covergaes for public and private health insurers. Such forward-looking statements are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Company may be unable to enter into definitive agreements, or close transactions with respect to, proposed future clinic openings; that due diligence with respect to anticipated clinic openings and acquisitions may not be satisfactory to the Company; risks related to delays in permitting or construction; risks related to supply chains and access to labour; that legislative changes may have an adverse effect on the Company's business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that the Company will be able to commence and/or complete build-outs and tenants improvements for new clinics; general business, economic, competitive, political and social uncertainties; and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur on the terms or in the time expected, or at all, or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.
SOURCE: Empower Clinics Inc.